MedTrace Logo

Ranibizumab for the Inhibition of Neovascularization in Pterygia

NCT00768963 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2017-07-11

No results posted yet for this study

Summary

The primary purpose of this trial is to evaluate the safety and tolerability of ranibizumab given via subconjunctival injection in patients undergoing pterygium surgery.

Conditions

  • Pterygium

Interventions

DRUG

ranibizumab

0.5 mg subconjunctival ranibizumab 3 days prior to surgery

DRUG

ranibizumab

0.5 mg subconjunctival ranibizumab at the time of surgery

Sponsors & Collaborators

  • University of Miami

    lead OTHER

Principal Investigators

  • Sonia Yoo, MD · Bascom Palmer Eye Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-10-31
Primary Completion
2011-11-30
Completion
2012-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00768963 on ClinicalTrials.gov